The management of polycystic ovary syndrome

Annals of the New York Academy of Sciences

Volumn 997, Issue , 2003, Pages 307-321

  Bruni, Vincenza ^a   Dei, Metella ^a   Pontello, Valentina ^a   Vangelisti, Paolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Hyperandrogenism; Infertility; Insulin; Menstruation; Obesity; Polycystic ovary syndrome (PCOS)

Indexed keywords

ACETYLCYSTEINE; ANTIANDROGEN; CYPROTERONE ACETATE; DIANE; DIENOGEST PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; FINASTERIDE; FLUTAMIDE; INOSITOL DERIVATIVE; INSULIN SENSITIZING AGENT; METFORMIN; NALTREXONE; OCTREOTIDE; ORAL CONTRACEPTIVE AGENT; ROSIGLITAZONE; SPIRONOLACTONE; TROGLITAZONE;

ANOREXIA; CONFERENCE PAPER; DIARRHEA; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; FEMALE INFERTILITY; HUMAN; HYPERANDROGENISM; LACTIC ACIDOSIS; LIFESTYLE; LIVER TOXICITY; LONG TERM CARE; MUSCLE CRAMP; NAUSEA; ORAL CONTRACEPTION; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; SIDE EFFECT; WEIGHT REDUCTION; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIET; FEMALE; HOSPITALIZATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

FALLOPIA;

ADULT; COMBINED MODALITY THERAPY; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; DIET; FEMALE; HUMANS; INFERTILITY, FEMALE; LIFE STYLE; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 0642364486     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1290.034     Document Type: Conference Paper

References (96)

1. ZAWANDRI, J.K. & A. DUNAIF. 1992. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In Polycystic Ovary Syndrome. Current Issues in Endocrinology and Metabolism. A. Dunaif, J.R. Givens, F.P. Haseltine, and G.R. Merriam, Eds.: 377-384. Blackwell. Boston.
2. ADAMS, J., S. FRANKS, D.W. POLSON, et al. 1985. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotrophin releasing hormone. Lancet ii: 1375-1378.
3. HOMBURG, R. 2002. What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome. Hum. Reprod. 17: 2495-2502.
4. LEGRO, R.S., D. FINEGOOD & A. DUNAIF. 1998. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83: 2694-2698.
5. IBANEZ, L., K. ONG, N. POTAU, et al. 2001. Insulin gene variable number of tandem repeat genotype and the low birth weight, precocious pubarche, and hyperinsulinism sequence. J. Clin. Endocrinol. Metab. 86: 5788-5792.
6. EHRMANN, D.A., X. TANG, I. YOSHIUCHI, et al. 2002. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87: 4297-4300.
7. WITCHEL, S.F., R. SMITH, M. TOMBOC, et al. 2001. Candidate gene analysis in premature pubarche and adolescent hyperandrogenism. Fertil. Steril. 75: 72-30.
8. MIFSUD, A., S. RAMIREZ & E.L. YONG. 2000. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J. Clin. Endocrinol. Metab. 85: 3484-3488.
9. ABBOTT, D.H., D.A. DUMESIC & S. FRANKS. 2002. Developmental origin of polycystic ovary syndrome - a hypothesis. J. Endocrinol. 174: 1-5.
10. JAHANFAR, S., J.A. EDEN, P. WARREN, et al. 1995. A twin study of polycystic ovary syndrome. Fertil. Steril. 63: 478-486.
11. AZZIZ, R., D. EHRMANN, R.S. LEGRO, et al. 2001. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 86: 1626-1632.
12. CIBULA, D., J. SKRHA, M. HILL, et al. 2002. Prediction of insulin sensitivity in non-obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87: 5821-5825.
13. CIAMPELLI, M., A. LANZONE, P. APA, et al. 1997. Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome. Hum. Reprod. 12: 1897-1901.
14. HOMBURG, R, 1996. Polycystic ovary syndrome: induction of ovulation. Baillier's Clin. Endocrinol. Metab. 10: 281-292.
15. DAHLGREN, E., L.G. FRIBERG, S. JOHANSSON, et al. 1991. Endometrial carcinoma; ovarian dysfunction-a risk factor in young women. Eur. J. Obstet. Gynecol. Reprod. Biol. 41: 143-150.
16. KIRCHENGAST, S. & J. HUBER. 2001. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum. Reprod. 16: 1255-1260.
17. MC CLUSKEY, S., C. EVANS, J.E. LACEY, et al. 1991. Polycystic ovary syndrome and bulimia. Fertil. Steril. 55: 946-951.
18. TALBOTT, E.O., J.V. ZBOROWSKI, K. SUTTON-TYRREL, et al. 2001. Cardiovascular risk in women with polycystic ovary syndrome. Obstet. Gynecol. North Am. 28: 111-133.
19. PIERPOINT, T., P.M. MCKEIGUE, A.J. ISAACS, et al. 1998. Mortality of women with polycystic ovary syndrome at long-term follow-up. J. Clin. Epidemiol. 51: 581-586.
20. LEGRO, R.S., A.R. KUNSELMAN, W.C. DODSON, et al. 1999. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 84: 165-169.
21. WILD, R.A. 2002. Polycystic ovary syndrome: a risk for coronary artery disease? Am. J. Obstet. Gynecol. 186: 35-43.
22. GLUECK, C.J., S.G. AWADALLA, H. PHILLIPS, et al. 2000. Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage. Fertil. Steril. 74: 394-397.
23. IBANEZ, L., C. AULESA, N. POTAU, et al. 2002. Plasminogen activator inhibitor-1 in girls with precocius pubarche: a premenarcheal marker for polycystic ovary syndrome? Pediatr. Res. 51: 244-248.
24. LOVERRO, G., F. LORUSSO, L. MEI, et al. 2002. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol. Obstet. Invest. 53: 157-162.
25. ROBINSON, S., S.V. HENDERSON, D. GELDING, et al. 1996. Dyslipidemia is associated with insulin resistance in women with polycystic ovaries. Clin. Endocrinol. (Oxf.) 44: 277-284.
26. PARADISI, G., H.O. STEINBERG, A. HEMPFLING, et al. 2001. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103: 1410-1415.
27. SABUNCU, T., H. VURAL, M. HARMA, et al. 2001. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin. Biochem. 34: 407-413.
28. HACIHANEFIOGLU, B., H. SEYISOGLU, K. KARDISAG, et al. 2000. Influence of insulin resitance on total renin level in normotensive women with polycystic ovary syndrome. Fertil. Steril. 73: 261-265.
29. KASHYAP, S. & P. CLAMAN. 2000. Polycystic ovary disease and the risk of pregnancy-induced hypertension. J. Reprod. Med. 45: 991-994.
30. WILD, S., T. PIERPOINT, P. MCKEIGUE, et al. 2000. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin. Endocrinol. (Oxf.) 52: 595-600.
31. CLARK, A.M., B. THORNLEY, L. TOMLINSON, et al. 1998. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum. Reprod. 13: 1502-1505.
32. KIDDY, D.S., D. HAMILTON-FAIRLEY, A. BUSH, et al. 1992. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 36: 105-111.
33. LANZONE, A., A.M. FULGHESU, A. FORTINI, et al. 1991. Effect of opiate receptor blockade on the insulin response to oral glucose load in polycystic ovarian disease. Hum. Reprod. 6: 1043-1049.
34. HOLTE, J., T. BERGH, C. BERNE, et al. 1995. J. Clin. Endocrinol. Metab. 80: 2586-2592.
35. PASQUALI, R., L. ANTENUCCI, R. ERKKOLA, et al. 1989. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J. Clin. Endocrinol. Metab. 68: 173-179.
36. VAN DER VANGE, N., M.A. BLANKESTEIN, H.J. KLOOSTERBOER, et al. 1990. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 41: 345-349.
37. WIEGRATZ, I., E. KUTSCHERA, J.H. LEE, et al. 2003. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 67: 25-32.
38. PETERSEN, K.R., S.O. SKOUBY & R.G. PEDERSEN. 1991. Desogestrel and gestodene in oral contraceptives: 12 months' assessment of carbohydrate and lipoprotein metabolism. Obstet. Gynecol. 78: 666-672.
39. SPELLACY, W.N, A.M. TSIBRIS, J.C. TSIBRIS, et al. 1994. Carbohydrate metabolism studies after one year of using an oral contraceptive containing gestodene and ethynil estradiol. Contraception 49: 125-30.
40. LUDICKE, F., U.J. GASPARD, F. DEMEYER, et al. 2002. Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. Cotraception 66: 411-415.
41. VAN DER VANGE, N., H.J. KLOOSTERBOER & A.A. HASPELS. 1987. Effects of seven low-dose oral contraceptive preparations on carbohydrate metabolism. Am. J. Obstet. Gynecol. 156: 918-922.
42. CIBULA, D., G. SINDELKA, M. HILL, et al. 2002. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. Hum. Reprod. 17: 76-82.
43. SKOUBY, S.O., O. ANDERSEN, N. SAURBREY, et al. 1987. Oral contraception and insulin sensitivity in vivo assessment in normal women and women with previous gestational diabetes. J. Clin. Endocrinol. Metab. 64: 519-523.
44. FALSETTI, L., A. GAMBERA & G. TISI. 2001. Efficacy of the combination ethinyloestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum. Reprod. 16: 36-42.
45. CIBULA, D., M. HILL & M. FANTA. 2001. Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovary syndrome? Hum. Reprod. 16: 940-944.
46. FALSETTI, L. & E. PASINETTI. 1995. Effect of long term administration of an oral contraceptive containing ethynilestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary sindrome. Acta Obstet. Gynecol. Scand. 74: 56-60.
47. CREATSAS, G., C. KOLIOPOULOS & G. MASTORAKOS. 2000. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann. N.Y. Acad. Sci. 900: 245-252.
48. VAN WAYIEN, R.G. & A. VAN DEN ENDE. 1995. Experience in the long-term treatment of patients with hisutism and/or acne with cyproterone acetate-containing preparations. Efficacy, metabolism and endocrine effects. Exp. Clin. Endocrinol. Diabetes 103: 241-251.
49. SCHEEN, A.J., B.J. JANDRAIN, D.M.,P. HUMBLET, et al. 1993. Effects of a 1-year treatment with a low-dose combined oral contraceptive containing ethinyl estradiol and cyproterone acetate on glucose and insulin metabolism. Fertil. Steril. 59: 797-802.
50. PRELEVIC, G.M., M.I. WURZBURGER, D. TRPKOVIC, et al. 1990. Effect of low-dose estrogen. Antiandrogen combination (Diane 35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome. Gynecol. Endocrinol. 4: 157-168.
51. ZIMMERMANN, T., K.H. WISSER & H. DIETRICH. 2000. The effects of Valette on skin and hair: a post-marketing surveillance study. Int. J. Clin. Pract. 54: 85-91.
52. RABE, T., A. KOWALD, J. ORTMANN, et al. 2000. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol. Endocrinol. 14: 223-230.
53. WIEGRATZ, I., E. KUTSCHERA, H.H. BAUER, et al. 2002. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception 65: 223-229.
54. THORNEYCROFT, I.H. 2002. Evolution of progestins. Focus on the novel progestin drospirenone. J. Reprod. Med. 47(Suppl.): 975-980.
55. BLODE, H., W WUTTKE, W LOOCK, et al. 2000. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur. J. Contracept. Reprod. Health Care 5: 256-264.
56. VAN VLOTEN, W.A., C.W. VAN HASELEN, E.J. VAN ZUUREN, et al. 2002. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhoea. Cutis 69(Suppl.): 2-15.
57. VARTIANEN, M., H. DE GEZELLE & C.J. BROEKMEULEN. 2001. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. Eur. J. Contracept. Reprod. Health Care 6: 46-49.
58. PASQUALI, R., A. GAMBINERI, B. ANCONETANI, et al. 1999. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progetagen treatment. Clin. Endocrinol. 50: 517-527.
59. DIAMANTI-KANDARAKIS, E., A. MITRAKU, S. RAPTIS, et al. 1998. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83: 2699-2705.
60. CIOTTA, L., A. CIANCI, E. MARLETTA, et al. 1994. Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovary patients. Fertil. Steril. 62: 1129-1135.
61. DE LEO, V., A. FULGHESU, A. LA MARCA, et al. 2000. Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism. Gynecol. Endocrinol. 14: 411-416.
62. EAGLESON, C.A., M.B. GINGRICH, C.L. PASTOR, et al. 2000. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotrophin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J. Clin. Endocrinol. Metab. 85: 4047-4052.
63. PAOLETTI, A.M., A. CAGNACCI, M. ORRU, et al. 1999. Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism. Fertil. Steril. 72: 448-453.
64. MUDERRIS, II., F. BAYRAM & M. GUVEN. 2000. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil. Steril. 73: 984-987.
65. FARQUHAR, C., O. LEE, R. TOOMATH, et al. 2001. Spironolactone versus placebo in combination with steroids for hirsutism and/or acne. Cochrane Database Syst. Rev. 4: CD000194.
66. BAYRAM, F., II. MUDERRIS & F. Kelestimur. 2002. Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism. Eur. J. Endocrinol. 147: 467-471.
67. FALSETTI, L. & E. PASINETTI. 1994. Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism. Fertil. Steril. 61: 817-822.
68. CARMINA, E. & R.A. LOBO. 1997. Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. Hum. Reprod. 12: 663-666.
69. CIOTTA, L., A. CIANCI, G. GIUFFRIDA, et al. 1996. Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease. Fertil. Steril. 65: 61-67.
70. CASTELO-BRANCO, C., C. MARTINEZ DE OSABA, F. PONS, et al. 1997. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism: effects on hair, bone, and hormonal profile after 1-year use. Metabolism 4: 437-440.
71. ROBINSON, S., D.S. KIDDY, S.V. GELDING, et al. 1993. The relationship of insulin sensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin. Endocrinol. 39: 351-355.
72. MORIN-PAPUNEN, L.C., I. VAUHKONEN, R.M. KOIVUNEN, et al. 2000. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J. Clin. Endocrinol. Metab. 85: 3161-3168.
73. MOGHETTI, P., R. CASTELLO, C. NEGRI, et al. 2000. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J. Clin. Endocrinol. Metab. 85: 139-145.
74. ARSLANIAN, S.A., V. LEWY, K. DANADIAN, et al. 2002. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J. Clin. Endocrinol. Metab. 87: 1555-1559.
75. PASQUALI, R., A. GAMBINERI, D. BISCOTTI, et al. 2000. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85: 2767-2774.
76. VELASQUEZ, E.M., S. MENDOZA, T. HAMER, et al. 1994. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43: 647-654.
77. VELASQUEZ, E.M., A. ACOSTA & S.G. MENDOZA. 1997. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet. Gynecol. 90: 392-395.
78. GLUECK, C.J., P. WANG, R. FONTAINE, et al. 1999. Metformin-induced resumption of normal menses in 39 of 43 (91%) of previously amenorrheic women with polycystic ovary syndrome. Metabolism 49: 511-519.
79. IBANEZ, L., C. VALLS, N. POTAU, et al. 2000. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J. Clin. Endocrinol. Metab. 85: 3526-3530.
80. GLUECK, C.J., P. WANG & R. FONTAINE. 2001. Metformin to restore normal menses in oligoamenorrheic teenage girls with polycystic ovary syndrome. J. Adolesc. Health 21: 160-169.
81. GLUECK, C.J., H. PHILLIPS, D. CAMERON, et al. 2001. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil. Steril. 75: 1126-1133.
82. NESTLER, J.E. & D.J. JACUBOWICZ. 1996. Decreases in ovarian cytochrome p450cl alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N. Engl. J. Med. 335: 617-623.
83. DIAMANTI, E., C. KOULI, T. TSIANATELLI, et al. 1998. Therapeutic effects of metformin therapy in polycystic ovary syndrome. Eur. J. Endocrinol. 138: 269-274.
84. KOLODZIEJCZYK, B., A.J. DULEBA & R.Z. SPACZYNSKI. 2000. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovariy syndrome. Fertil. Steril. 73: 1149-1154.
85. DE LEO, V., A. LA MARCA, R. ORVIETO, et al. 2000. Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85: 1598-1600.
86. KELLY, C.J. & D. GORDON. 2002. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur. J. Endocrinol. 147: 217-221.
87. DE FRONZO, R.A., N. BARZILAI & D. SIMONSON. 1991. Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J. Clin. Endocrinol. Metab. 73: 1294-1301.
88. AZZIZ, R., R.S. EHRMANN, R.W. LEGRO, et al. 2001. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 86: 1626-1632.
89. NESTLER, J.E., D.J. JAKUBOWICZ, P. REAMER, et al. 1999. Ovulatory and metabolic effects of D-chiro.inositol in the polycystic ovary syndrome. N. Engl. J. Med. 340: 1314-1320.
90. NESTLER, J.E., D. STOVALL, N. AKHTER, et al. 2002. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil. Steril. 77: 209-215.
91. IBANEZ, L., C. VALLS, A. FERRER, et al. 2002. Additive effect of insulin-sensitizing and anti-androgen teratment in young, nonobese women with hyperinsulinism, hyperandrogenism, dysilipidemia, and anovulation. J. Clin. Endocrinol. Metab. 87: 2870-2874.
92. IBANEZ, L. & F. DE ZEGHER. 2003. Low dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycsytic ovary syndrome. Hum. Reprod. 18: 57-60.
93. FRUZZETTI, F., C. BERSI, D. PARRINI, et al. 2002. Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil. Steril. 77: 936-944.
94. LANZONE, A., A.M. FULGHESU, M. GUIDO, et al. 1997. Somatostatin treatment reduces the exaggerated response of adrenocorticotropin hormone and cortisol to corticotropin-releasing hormone in polycystic ovary syndrome. Fertil. Steril. 67: 34-39.
95. VAN DER MEER, M., J.A. DE BOER, P.G. HOMPES, et al. 1998. Octreotide, a somatostatin analogue, alters ovarian sensitivity to gonadotrophin stimulation as measured by the follicle stimulating hormone threshold in polycystic ovary syndrome. Hum. Reprod. 13: 1465-1469.
96. FULGHESU, A. M., M. CIAMPELLI, G. MUZJ, et al. 2001. N-Acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil. Steril. 77: 1128-1135.